Maintenance treatment in multiple myeloma: A new era

Bookmark and Share
This video is restricted to members who are registered with ecancer as a healthcare professional
Please login or register for free to confirm your details.
Published: 18 Jun 2020
Views: 2141
Prof Sagar Lonial and Prof Wee-Joo Chng

Prof Sagar Lonial (Emory University, Atlanta, USA) and Prof Wee-Joo Chng (Cancer Science Institute of Singapore, Singapore) discuss the latest advances in the maintenance treatment of patients with multiple myeloma from EHA 2020

The experts begin by discussing the use of proteasome inhibitors in the maintenance setting.

Prof Chng gives an overview of the latest results from the TOURMALINE-MM4 study, which is investigating the use of ixazomib as a post-induction maintenance therapy in non-transplant eligible newly-diagnosed multiple myeloma (NDMM) patients.

Prof Lonial and Prof Chng go on to discuss the benefits of using oral agents, such as ixazomib - particularly during the times of COVID-19.

Prof Lonial describes the design of the TOURMALINE-MM4 trial, and the experts outline which patients may benefit from this type of treatment.

Prof Lonial and Prof Chng conclude by expressing their thoughts on the length of maintenance therapy, and explain when clinicians should make the transition from induction to maintenance treatment.

This programme has been supported by an unrestricted educational grant from Takeda.